title: [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
authors.affiliation: Geschäftsstelle der AUO, MeckEvidence, Seestraße 11 , 17252 Schwarz, Deutschland. AUO@MeckEvidence.de
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality*; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000401:mortality* / Q000628:therapy*; D009392:Nephrectomy / Q000706:statistics & numerical data*; D015990:Placebo Effect; D015995:Prevalence; D011743:Pyrimidines / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use*; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib